CIK 0001439222 · Large accelerated filer
AGIOS PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- AGIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-649-8600
- Business address
- 88 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- AGIOS PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $371,112
- in 2 filings, $371K under 10b5-1 plans
Net −$371,112. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-24 | Burns James William Chief Legal Officer | Sale 10b5-1 | −1,708 | $21.64 | $37K | 30,378 |
| 2024-01-24 | Gheuens Sarah Chief Medical Officer | Sale 10b5-1 | −1,708 | $21.64 | $37K | 31,911 |
| 2024-01-24 | Jones Cecilia Chief Financial Officer | Sale 10b5-1 | −1,886 | $21.64 | $41K | 13,069 |
| 2024-01-24 | FOUSE JACQUALYN A Director | Sale 10b5-1 | −10,722 | $21.64 | $232K | 129,253 |
| 2024-01-24 | Goff Brian Chief Executive Officer | Sale 10b5-1 | −7,635 | $21.64 | $165K | 49,436 |
| 2024-01-24 | Milanova Tsveta Chief Commercial Officer | Sale 10b5-1 | −1,618 | $21.64 | $35K | 13,234 |
| 2024-01-20 | Burns James William Chief Legal Officer | Option exercise 10b5-1 | +5,750 | 32,086 | ||
| 2024-01-20 | Burns James William Chief Legal Officer | Option exercise · Performance share units 10b5-1 | −5,750 | 0 | ||
| 2024-01-20 | Gheuens Sarah Chief Medical Officer | Option exercise 10b5-1 | +5,750 | 33,619 | ||
| 2024-01-20 | Gheuens Sarah Chief Medical Officer | Option exercise · Performance share units 10b5-1 | −5,750 | 0 | ||
| 2024-01-20 | Jones Cecilia Chief Financial Officer | Option exercise 10b5-1 | +5,380 | 14,955 | ||
| 2024-01-20 | Jones Cecilia Chief Financial Officer | Option exercise · Performance share units 10b5-1 | −5,380 | 0 | ||
| 2024-01-20 | FOUSE JACQUALYN A Director | Option exercise 10b5-1 | +23,900 | 139,975 | ||
| 2024-01-20 | FOUSE JACQUALYN A Director | Option exercise · Performance share units 10b5-1 | −23,900 | 0 | ||
| 2024-01-20 | Goff Brian Chief Executive Officer | Option exercise 10b5-1 | +17,018 | 57,071 | ||
| 2024-01-20 | Goff Brian Chief Executive Officer | Option exercise · Performance share units 10b5-1 | −17,018 | 102,110 | ||
| 2024-01-20 | Milanova Tsveta Chief Commercial Officer | Option exercise 10b5-1 | +5,448 | 14,852 | ||
| 2024-01-20 | Milanova Tsveta Chief Commercial Officer | Option exercise · Performance share units 10b5-1 | −5,448 | 0 | ||
| 2024-01-09 | Goff Brian Chief Executive Officer | Sale 10b5-1 | −12,066 | $22.99 | $277K | 40,053 |
| 2024-01-09 | FOUSE JACQUALYN A Director | Sale 10b5-1 | −8,391 | $22.99 | $193K | 116,075 |
Page 25 of 48 · 941 trades